Introduction Colitis-associated colorectal cancer (caCRC) represents a distinct subtype of colorectal cancer that develops in patients with long-standing Inflammatory Bowel Disease, particularly Ulcerative Colitis and Crohn’s Disease. With the rising global burden of IBD, the population at risk for caCRC is steadily increasing.
Introduction
Colitis-associated colorectal cancer (caCRC) represents a distinct subtype of colorectal cancer that develops in patients with long-standing Inflammatory Bowel Disease, particularly Ulcerative Colitis and Crohn’s Disease. With the rising global burden of IBD, the population at risk for caCRC is steadily increasing. Unlike sporadic colorectal cancer, caCRC arises in a background of chronic inflammation, leading to unique molecular, cellular, and microenvironmental changes that influence tumor initiation and progression.
Problem Statement
Despite improved control of inflammation in IBD, caCRC remains a major clinical challenge because its pathogenesis is complex, heterogeneous, and fundamentally different from sporadic colorectal cancer, making early detection, risk stratification, and targeted therapy difficult.
Summary
This review highlights that caCRC is driven primarily by chronic inflammation-induced epithelial damage and regeneration. Persistent barrier disruption accelerates epithelial aging and promotes early genetic alterations—particularly early loss of p53, unlike the adenoma–carcinoma sequence seen in sporadic colorectal cancer. Inflammatory pathways such as IL-17 and NF-κB play a central role in early tumorigenesis. The tumor microenvironment is equally critical, involving dynamic interactions between epithelial cells, immune cells, cancer-associated fibroblasts, and the gut microbiome. Dysbiosis further amplifies inflammatory signaling and tumor promotion. caCRC is also characterized by rapid progression and a tendency toward mesenchymal tumor phenotypes, contributing to aggressive behavior. Importantly, the review emphasizes that future management will likely shift toward personalized strategies targeting inflammation, microbiome modulation, immune pathways, and stromal interactions to prevent and treat caCRC more effectively.
Introduction: The global incidence of inflammatory bowel disease (IBD) continues to rise, particularly in newly industrialized countries. This comprehensive systematic review evaluated how race, ethnicity, geography, and migration influence the clinical phenotype and outcomes of...
Introduction: Acute severe ulcerative colitis (ASUC) remains one of the most life-threatening emergencies in inflammatory bowel disease. Despite advances in IBD therapy, first-line management has changed little over the past two decades, and colectomy continues...
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising global burden. Although current therapies are effective, many patients fail treatment or experience adverse effects. Fecal microbiota transplantation (FMT) has emerged as...
Introduction: Despite major advances with biologics and small molecules, many patients with IBD continue to have refractory disease or lose treatment response. This Perspective explores engineered cellular therapies designed to restore immune tolerance rather than...
Introduction: Randomized clinical trials (RCTs) are the cornerstone for approving biologic therapies in inflammatory bowel disease (IBD). However, strict eligibility criteria may exclude many patients encountered in routine clinical practice, raising concerns about the real-world...
Introduction: Mirikizumab, a selective IL-23p19 inhibitor, has demonstrated efficacy in phase III clinical trials for moderate-to-severe ulcerative colitis (UC). This multicenter Italian real-world study evaluated its effectiveness and safety in routine clinical practice, including patients...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.